Table 6 Comparison of phenotypic antimicrobial resistance prevalence in this study with some studies in Iran and other regions of the world
Region | Year | Authors | Method | Sample size and origin | CTX | CAZ | CRO | AZT | CP |
|---|---|---|---|---|---|---|---|---|---|
This study | 2023 | Afshari et al | Disk diffusion test | 106 E. coli isolates from 168 UTI cases | 88.6% | 76.4% | 77% | 83% | 55.6% |
Iran | 2022 | Sadeghi et al | Disk diffusion test | 263 E. coli isolates from UTI cases | NA | 55.1% | 56.3% | 52.1% | 56.3% |
Iran (Jiroft) | 2018 | Mashaiekhi et al | Disk diffusion test | 181 E.coli isolates from UTI cases | 36.4% | 45.3% | NS | NS | 31.4% |
Iran | 2015 | Harifi Mood et al | Disk diffusion test | 200 E. coli isolates from clinical specimens | 52% | 46.5% | NS | NS | 43% |
China | 2020 | Sun et al | Vitek Compact 2 system | 7713 non-repetitive UPEC isolates | NS | 26.1% | 54% | 39.6% | 61.8% |
Ethiopia | 2020 | Dadi et al | Disk diffusion test | 200 E. coli isolates from 780 UTI cases | 66% | 84% | 80.5% | NS | 14.5% |
Nigeria | 2012 | Ejikeugwu et al | Disk diffusion test | 83 E. coli isolates from suspected UTI cases | 76% | 64% | 34% | NS | 47% |
Spain | 2022 | Gaviria et al | MIC | 26 E. coli isolates from 30 UTI cases | 100% | 53.8% | NS | NS | 80.7% |
Cyprus | 2016 | Cantas et al | BD Phoenix ™ | 389 E. coli isolates from Cystitis cases | NS | 75%a | 80%a | 90%a | 90%a |
USA | 2019 | Critchley et al | MIC | 1831 E. coli isolates from UTI cases | NS | 8.5% | NS | NS | 25.8% |
USA | 2016 | Lob et al | MIC | 3498 E. coli isolates from UTI cases | 19.3% | 16.8% | 19.5% | NS | 35.3% |
Canada | 2016 | Lob et al | MIC | 3498 E. coli isolates from UTI cases | 14.8% | 8.3% | 14.3% | NS | 25.5% |